GUANGZHOU, China, July 9 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME; " China Medicine" or " the Company"), a leading distributor and developer of ethical and over-the-counter drugs, traditional Chinese Medicine (TCM), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China (PRC), announced today that it released a white paper on Recombinant Aflatoxin-Detoxifizyme ("rADTZ"). The paper describes the origin, development and history of rADTZ, its scientific basis, and its market potential in the feed, food and health care industries. The white paper is available for download on the Company's website: http://www.chinamedicinecorp.com/adtz.htm .
"We are very excited about the development of rADTZ, which has the potential to detoxify aflatoxin (AFT) in food and feed, and we are currently carrying out experiments on animal feed," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "We hope to bring you positive news on the results in the near future."
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over-the-counter drugs, traditional Chinese medicine products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces and to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com .
This press release contains forward-looking statements concerning the
Company's business and products. The Company's actual results may differ
materially depending on a number of risk factors including, but not limited
to, the following: general economic and business conditions, obtaining
regulatory approval for new products, the expected contribution of higher
margin products, government support for rural health care, competition from
existing and new competitors, changes in technology, and various other
factors beyond its control. All forward-looking statements are expressly
qualified in their entirety by this Cautionary Statement and the risk
factors detailed in the Company's reports filed with the Securities and
Exchange Commission. China Medicine Corporation undertakes no duty to
revise or update any forward-looking statement to reflect events or
circumstances after the date of this release.
Ms. Huizhen Yu
Chief Financial Officer
China Medicine Corp.
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Elite Investor Relations
Mr. Richard Micchelli, Financial Writer
CCG Elite Investor Relations
|SOURCE China Medicine Corporation|
Copyright©2008 PR Newswire.
All rights reserved